Symptom aggravation after withdrawal of metal chelating agent therapy in patients with Wilson's disease

被引:2
作者
Zhou, Xiangxue [1 ]
Liao, Jian [1 ]
Liu, Yinjie [1 ]
Qin, Haolin [2 ]
Xiao, Xia [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangdong Prov Key Lab Diag & Treatment Major Neur, 58 Zhongshan Rd, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Imaging, Guangzhou, Peoples R China
来源
BRAIN AND BEHAVIOR | 2023年 / 13卷 / 09期
关键词
disease stage; drug discontinuance; metal chelating agent; symptoms aggravated; Wilson disease;
D O I
10.1002/brb3.3170
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
ObjectiveTo study the aggravation of clinical symptoms after discontinuation of metal chelating agent therapy in Wilson's disease (WD) patients, analyze the causes of aggravation, and observe the prognosis. Methods40 WD patients (cerebral type 30 cases and hepatic type 10 cases) who stopped using metal chelating agent were selected, 40 WD patients with normal therapy, and 10 normal control cases were selected. All patients underwent neurological symptom evaluation using modified Young scale, Child-Pugh liver function grading, metal metabolism, and disease typing. Magnetic sensitivity imaging (SWI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy imaging (MRS) were performed. According to the imaging results, WD patients were divided into metal deposition stage, fiber damage stage, and neuron necrosis stage. All patients were treated with metal chelating agent for 6 months. ResultsThe score of modified Young scale in drug withdrawal group was lower than that in normal treatment group before drug withdrawal (p = .032). The score of modified Young scale was higher after drug withdrawal than before (p = .011). The number of Child-Pugh B-grade patients after drug withdrawal was more than that before drug withdrawal and in normal treatment group. The proportion of patients in the stage of neuronal necrosis after drug withdrawal (25%) was higher than that before drug withdrawal (10%) (p = .025). After drug withdrawal, urine copper was significantly higher than that before drug withdrawal and in the normal treatment group (p = .032, .039). After the withdrawal group resumed metal chelating agent treatment, 34.2% of neurological symptoms worsened. ConclusionsWD patients showed neurological symptoms aggravation and increased liver injury after metal chelating agent withdrawal. Increased metal deposition and new nerve injury occurred in the brain. After re-treatment, the aggravated neurological symptoms of WD patients are difficult to reverse.
引用
收藏
页数:8
相关论文
共 37 条
  • [21] Brain proton magnetic spectroscopy in long-term treatment of Wilson's disease patients
    Tarnacka, Beata
    Szeszkowski, Wojciech
    Golebiowski, Marek
    Czlonkowska, Anna
    METABOLIC BRAIN DISEASE, 2010, 25 (04) : 375 - 379
  • [22] Brain proton magnetic spectroscopy in long-term treatment of Wilson's disease patients
    Tarnacka, Beata
    Szeszkowski, Wojciech
    Golebiowski, Marek
    Czlonkowska, Anna
    METABOLIC BRAIN DISEASE, 2010, 25 (03) : 325 - 329
  • [23] Brain proton magnetic spectroscopy in long-term treatment of Wilson’s disease patients
    Beata Tarnacka
    Wojciech Szeszkowski
    Marek Gołębiowski
    Anna Członkowska
    Metabolic Brain Disease, 2010, 25 : 325 - 329
  • [24] Brain proton magnetic spectroscopy in long-term treatment of Wilson’s disease patients
    Beata Tarnacka
    Wojciech Szeszkowski
    Marek Gołębiowski
    Anna Członkowska
    Metabolic Brain Disease, 2010, 25 : 375 - 379
  • [25] Optimized Trientine-dihydrochloride Therapy in Pediatric Patients With Wilson Disease: Is Weight-based Dosing Justified?
    Mayr, Toni
    Ferenci, Peter
    Weiler, Markus
    Fichtner, Alexander
    Mehrabi, Arianeb
    Hoffmann, Georg Friedrich
    Mohr, Isabelle
    Pfeiffenberger, Jan
    Weiss, Karl Heinz
    Teufel-Schafer, Ulrike
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 72 (01) : 115 - 122
  • [26] Metal Element Excretion in 24-h Urine in Patients with Wilson Disease under Treatment of d-Penicillamine
    Lisu Huang
    Xiaodan Yu
    Jun Zhang
    Xiaoqing Liu
    Yongjun Zhang
    Xianting Jiao
    Xiaogang Yu
    Biological Trace Element Research, 2012, 146 : 154 - 159
  • [27] Metabolic changes in 37 newly diagnosed Wilson's disease patients assessed by magnetic resonance spectroscopy
    Tarnacka, B.
    Szeszkowski, W.
    Golebiowski, M.
    Czlonkowska, A.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (08) : 582 - 586
  • [28] Metal Element Excretion in 24-h Urine in Patients with Wilson Disease under Treatment of d-Penicillamine
    Huang, Lisu
    Yu, Xiaodan
    Zhang, Jun
    Liu, Xiaoqing
    Zhang, Yongjun
    Jiao, Xianting
    Yu, Xiaogang
    BIOLOGICAL TRACE ELEMENT RESEARCH, 2012, 146 (02) : 154 - 159
  • [29] Liver changes in Wilson's disease: the full spectrum. A report of 127 biopsies from 43 patients
    Fanni, D.
    Guido, M.
    Gerosa, C.
    Vallascas, V.
    Moi, M.
    Coni, P.
    Vallebona, E.
    Van Eyken, P.
    Barcellona, D.
    Scano, A.
    Orru, G.
    Pampaloni, P.
    Castagnola, M.
    Faa, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (12) : 4336 - 4344
  • [30] Genetic studies discover novel coding and non-coding mutations in patients with Wilson's disease in China
    Huang, Chenjun
    Fang, Meng
    Xiao, Xiao
    Gao, Zhiyuan
    Wang, Ying
    Gao, Chunfang
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (06)